Test Code AIAES Axonal Neuropathy, Autoimmune/Paraneoplastic Evaluation, Serum
Ordering Guidance
Multiple neurological phenotype-specific autoimmune/paraneoplastic evaluations are available. For more information as well as phenotype-specific testing options, see Autoimmune Neurology Test Ordering Guide.
When more than one evaluation is ordered on the same order number, the duplicate test will be canceled.
For a list of antibodies performed with each evaluation, see Autoimmune Neurology Antibody Matrix.
This test should not be requested for patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed or canceled if radioactivity remains.
Necessary Information
Provide the following information:
-Relevant clinical information
-Ordering healthcare professional's name, phone number, mailing address, and email address
Specimen Required
Patient Preparation: For optimal antibody detection, collect specimen before starting immunosuppressant medication or intravenous immunoglobulin treatment.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 4 mL Serum
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Secondary ID
606974Useful For
Evaluation of patients who present with a subacute neurological disorder of undetermined etiology, especially those with known risk factors for cancer using serum specimens
Directing a focused search for cancer
Investigating neurological symptoms that appear during, or after, cancer therapy, and are not explainable by metastasis
Differentiating autoimmune neuropathies from neurotoxic effects of chemotherapy
Detecting early evidence of cancer recurrence in previously seropositive patients
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| AIAEI | Autoimmune Axonal Interp, S | No | Yes |
| AMPHS | Amphiphysin Ab, S | No | Yes |
| AGN1S | Anti-Glial Nuclear Ab, Type 1 | No | Yes |
| ANN1S | Anti-Neuronal Nuclear Ab, Type 1 | No | Yes |
| ANN3S | Anti-Neuronal Nuclear Ab, Type 3 | No | Yes |
| APBIS | AP3B2 IFA, S | No | Yes |
| CS2CS | CASPR2-IgG CBA, S | No | Yes |
| CRMS | CRMP-5-IgG, S | No | Yes |
| IG5CS | IgLON5 CBA, S | No | Yes |
| LG1CS | LGI1-IgG CBA, S | No | Yes |
| PCAB2 | Purkinje Cell Cytoplasmic Ab Type 2 | No | Yes |
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| AGNBS | AGNA-1 Immunoblot, S | No | No |
| AGNTS | AGNA-1 Titer, S | No | No |
| APHTS | Amphiphysin Ab Titer, S | No | No |
| AMIBS | Amphiphysin Immunoblot, S | No | No |
| AN1BS | ANNA-1 Immunoblot, S | No | No |
| AN1TS | ANNA-1 Titer, S | No | No |
| AN2BS | ANNA-2 Immunoblot, S | No | No |
| AN3TS | ANNA-3 Titer, S | No | No |
| APBCS | AP3B2 CBA, S | No | No |
| APBTS | AP3B2 IFA Titer, S | No | No |
| CRMTS | CRMP-5-IgG Titer, S | No | No |
| IG5TS | IgLON5 IFA Titer, S | No | No |
| MP1BS | MAP1B Immunoblot, S | No | No |
| PC2TS | PCA-2 Titer, S | No | No |
| CRMWS | CRMP-5-IgG Western Blot, S | No | No |
Testing Algorithm
If the indirect immunofluorescence assay (IFA) patterns suggest antiglial nuclear antibody-1 (AGNA-1), then the AGNA-1 antibody IFA titer and AGNA-1 antibody immunoblot will be performed at an additional charge.
If the IFA patterns suggest antineuronal nuclear antibody type 1 (ANNA-1), then the ANNA-1 IFA titer, ANNA-1 immunoblot, and ANNA-2 immunoblot will be performed at an additional charge.
If the IFA pattern suggests ANNA-3 antibody or the client requests it, then the ANNA-3 IFA titer will be performed at an additional charge.
If the IFA pattern suggests PCA-2 antibody, then the PCA-2 antibody IFA titer and MAP1B immunoblot will be performed at an additional charge.
If the IFA patterns suggest amphiphysin antibody, then the amphiphysin antibody IFA titer and amphiphysin antibody immunoblot will be performed at an additional charge.
If the IFA patterns suggest collapsin response-mediator protein-5 (CRMP-5)-IgG, then the CRMP-5-IgG IFA titer and CRMP-5-IgG Western blot will be performed at an additional charge.
If the IFA pattern suggests adaptor protein 3 beta2 (AP3B2) antibody, then the AP3B2 antibody IFA titer and AP3B2 antibody CBA will be performed at an additional charge.
If the IgLON family member 5 antibody (IgLON5) by CBA result is positive, then the IgLON5 antibody IFA titer will be performed at an additional charge.
For more information see:
-Autoimmune/Paraneoplastic Axonal Neuropathy Evaluation Algorithm.
Method Name
AIAEI: Technical Interpretation
AMPHS, AGN1S, ANN1S, ANN3S, APBIS, CRMS, PCAB2, AGNTS, AN1TS, AN3TS, APBTS, APHTS, CRMTS, IG5TS, PC2TS: Indirect Immunofluorescence Assay (IFA)
CS2CS, IG5CS, LG1CS, APBCS: Cell Binding Assay (CBA)
CRMWS: Western Blot (WB)
AGNBS, AMIBS, AN1BS, AN2BS, MP1BS: Immunoblot (IB)
Reporting Name
Axonal, Autoimm/Paraneo, SSpecimen Type
SerumSpecimen Minimum Volume
Serum: 2 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 28 days |
| Frozen | 28 days | |
| Ambient | 72 hours |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Reference Values
|
Test ID |
Reporting name |
Methodology |
Reference value |
|
AIAEI |
Autoimmune Axonal Interp, S |
Technical interpretation |
Interpretive report |
|
AMPHS |
Amphiphysin Ab, S |
IFA |
Negative |
|
AGN1S |
Anti-Glial Nuclear Ab, Type 1 |
IFA |
Negative |
|
ANN1S |
Anti-Neuronal Nuclear Ab, Type 1 |
IFA |
Negative |
|
ANN3S |
Anti-Neuronal Nuclear Ab, Type 3 |
IFA |
Negative |
|
APBIS |
AP3B2 IFA, S |
IFA |
Negative |
|
CS2CS |
CASPR2-IgG CBA, S |
CBA |
Negative |
|
CRMS |
CRMP-5-IgG, S |
IFA |
Negative |
|
IG5CS |
IgLON5 CBA, S |
CBA |
Negative |
|
LG1CS |
LGI1-IgG CBA, S |
CBA |
Negative |
|
PCAB2 |
Purkinje Cell Cytoplasmic Ab Type 2 |
IFA |
Negative |
Reflex Information:
|
Test ID |
Reporting name |
Methodology |
Reference value |
|
AGNBS |
AGNA-1 Immunoblot, S |
IB |
Negative |
|
AGNTS |
AGNA-1 Titer, S |
IFA |
<1:240 |
|
APHTS |
Amphiphysin Ab Titer, S |
IFA |
<1:240 |
|
AMIBS |
Amphiphysin Immunoblot, S |
IB |
Negative |
|
AN1BS |
ANNA-1 Immunoblot, S |
IB |
Negative |
|
AN1TS |
ANNA-1 Titer, S |
IFA |
<1:240 |
|
AN2BS |
ANNA-2 Immunoblot, S |
IB |
Negative |
|
AN3TS |
ANNA-3 Titer, S |
IFA |
<1:240 |
|
APBCS |
AP3B2 CBA, S |
CBA |
Negative |
|
APBTS |
AP3B2 IFA Titer, S |
IFA |
<1:240 |
|
CRMTS |
CRMP-5-IgG Titer, S |
IFA |
<1:240 |
|
CRMWS |
CRMP-5-IgG Western Blot, S |
WB |
Negative |
|
IG5TS |
IgLON5 IFA Titer, S |
IFA |
<1:240 |
|
MP1BS |
MAP1B Immunoblot, S |
IB |
Negative |
|
PC2TS |
PCA-2 Titer, S |
IFA |
<1:240 |
*Methodology abbreviations:
Cell-binding assay (CBA)
Immunoblot (IB)
Immunofluorescence assay (IFA)
Western blot (WB)
Day(s) Performed
Profile tests: Monday through Sunday; Reflex tests: Varies
Report Available
8 to 12 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86255 x 10
84182 AGNBS (if appropriate)
86256 AGNTS (if appropriate)
86256 APHTS (if appropriate)
84182 AMIBS (if appropriate)
84182 AN1BS (if appropriate)
86256 AN1TS (if appropriate)
84182 AN2BS (if appropriate)
86256 AN3TS (if appropriate)
86255 APBCS (if appropriate)
86256 APBTS (if appropriate)
86256 CRMTS (if appropriate)
84182 CRMWS (if appropriate)
86256 IG5TS (if appropriate)
84182 MP1BS (if appropriate)
86256 PC2TS (if appropriate)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| AIAES | Axonal, Autoimm/Paraneo, S | 94695-4 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 606950 | IgLON5 CBA, S | 96478-3 |
| 615863 | AP3B2 IFA, S | 101907-4 |
| 89080 | AGNA-1, S | 84927-3 |
| 81722 | Amphiphysin Ab, S | 72327-0 |
| 80150 | ANNA-1, S | 33615-6 |
| 83137 | ANNA-3, S | 43102-3 |
| 83077 | CRMP-5-IgG, S | 72504-4 |
| 83138 | PCA-2, S | 84925-7 |
| 64279 | LGI1-IgG CBA, S | 94287-0 |
| 64281 | CASPR2-IgG CBA, S | 94285-4 |
| 606975 | Autoimmune Axonal Interp, S | 69048-7 |
| 618900 | IFA Notes | 48767-8 |